References
1. C G, M G, V R, MF D. Neonatal Cancer Epidemiology and Outcome: A Retrospective Study. J Pediatr Hematol Oncol . 2020;42(5):e286-e292. doi:10.1097/MPH.0000000000001692
2. D O, S S, HJ B, et al. Neonatal cancer. Lancet Oncol . 2013;14(13). doi:10.1016/S1470-2045(13)70236-5
3. Fletcher C, Unni K, Mertens F. Pathology and Genetics of Tumours of Soft Tissue and Bone . 3rd ed. (Fletcher C, Unni K, Mertens F, eds.).; 2002.
4. I S, M C, U A-J, C M, C R-G, A F. Soft tissue sarcomas in the first year of life. Eur J Cancer . 2010;46(13):2449-2456. doi:10.1016/J.EJCA.2010.05.002
5. Xiong J, Zhu K, Mao J, et al. Ewing-like sarcoma/undifferentiated round cell sarcoma in an infant with APC and MSH6 variation: A case report. Medicine (Baltimore) . 2019;98(45):e17872. doi:10.1097/MD.0000000000017872
6. YC K, YS S, P A, et al. NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations. Mod Pathol . 2020;33(7):1341-1349. doi:10.1038/S41379-020-0495-2
7. Lee CH, MariƱo-Enriquez A, Ou W, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol . 2012;36(5):641-653. doi:10.1097/PAS.0B013E31824A7B1A
8. Guizard M, Karanian M, Dijoud F, et al. Neonatal Soft Tissue Sarcoma with YWHAE-NUTM2B Fusion. Case Rep Oncol . 2019;12(2):631-638. doi:10.1159/000502227
9. Kao YC, Sung YS, Zhang L, et al. Recurrent BCOR Internal Tandem Duplication and YWHAE - NUTM2B Fusions in Soft Tissue Undifferentiated Round Cell Sarcoma of Infancy: Overlapping Genetic Features with Clear Cell Sarcoma of Kidney. Am J Surg Pathol . 2016;40(8):1009-1020. doi:10.1097/PAS.0000000000000629
10. Thibodeau ML, Bonakdar M, Zhao E, et al. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma.NPJ Precis Oncol . 2018;2(1). doi:10.1038/S41698-018-0050-5
11. Karlsson J, Valind A, Gisselsson D. BCOR internal tandem duplication and YWHAE-NUTM2B/E fusion are mutually exclusive events in clear cell sarcoma of the kidney. Genes Chromosom Cancer . 2016;55(2):120-123. doi:10.1002/gcc.22316
12. W D, D G, CA P, et al. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin. Lab Invest . 2013;93(10):1115-1127. doi:10.1038/LABINVEST.2013.98
13. BK L. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol . 2005;56(1):47-60. doi:10.1016/J.CRITREVONC.2004.09.009
14. H W, X G, Y D, B Z, Y G. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma. Pediatr Dermatol . 2018;35(5):635-638. doi:10.1111/PDE.13600
15. Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer . 2017;141(4):848-855. doi:10.1002/IJC.30775
16. L K, Z W, W Y, K D, X X. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol . 2014;140(3):471-476. doi:10.1007/S00432-013-1549-3
17. Z W, C Z, H S, et al. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.Dermatology . 2020;236(3):262-270. doi:10.1159/000503604
18. Lee J, Hong EM, Kim JH, et al. Metformin Induces Apoptosis and Inhibits Proliferation through the AMP-Activated Protein Kinase and Insulin-like Growth Factor 1 Receptor Pathways in the Bile Duct Cancer Cells. J Cancer . 2019;10(7):1734-1744. doi:10.7150/JCA.26380
19. Lei Y, Yi Y, Liu Y, et al. Metformin targets multiple signaling pathways in cancer. Chin J Cancer . 2017;36(1). doi:10.1186/S40880-017-0184-9
20. Ritter MR, Dorrell MI, Edmonds J, Fallon Friedlander S, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. 2002. www.pnas.orgcgidoi10.1073pnas.102185799. Accessed August 28, 2021.
21. A P, E B, ZA K, et al. IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma. Pediatr Res . 2008;63(3):263-267. doi:10.1203/PDR.0B013E318163A243
22. Y Y, J W-S, E B, JB M, J B. Genomic imprinting of IGF2 is maintained in infantile hemangioma despite its high level of expression. Mol Med . 2004;10(7-12):117-123. doi:10.2119/2004-00045.BISCHOFF
23. M M, M K, R L, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood . 2006;108(5):1744-1750. doi:10.1182/BLOOD-2006-04-016634
24. TW L, SG D, L M, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol . 2018;19(5):705-714. doi:10.1016/S1470-2045(18)30119-0
25. Doebele RC, Davis LE, Vaishnavi A, et al. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov . 2015;5(10):1049-1057. doi:10.1158/2159-8290.CD-15-0443
26. A G, JA B, KM S, et al. Infantile fibrosarcoma-like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib. Cold Spring Harb Mol case Stud . 2020;6(5). doi:10.1101/MCS.A005645
27. Penning AJ, Al-Ibraheemi A, Michal M, et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. Mod Pathol 2021 348 . 2021;34(8):1530-1540. doi:10.1038/s41379-021-00806-w
28. CP W, ML E, I J, AC T, RL J, PH H. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Rev Anticancer Ther . 2019;19(11):971-991. doi:10.1080/14737140.2019.1686979
29. Weiss MC, Agulnik M. Tazemetostat as a treatment for epithelioid sarcoma. https://doi.org/101080/2167870720201809377 . 2020;8(9):311-315. doi:10.1080/21678707.2020.1809377
30. J K, H L, L HM, et al. Activation of human telomerase reverse transcriptase through gene fusion in clear cell sarcoma of the kidney.Cancer Lett . 2015;357(2):498-501. doi:10.1016/J.CANLET.2014.11.057
31. A T, TL L, KH B, et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med . 2015;373(10):908-919. doi:10.1056/NEJMOA1310523
32. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med . 2015;373(10):920-928. doi:10.1056/NEJMOA1503479/SUPPL_FILE/NEJMOA1503479_DISCLOSURES.PDF
33. Jafri MA, Ansari SA, Alqahtani MH, Shay JW. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.Genome Med 2016 81 . 2016;8(1):1-18. doi:10.1186/S13073-016-0324-X